Evidence map›Paper›PMID 30096073›Full record

SynthesisAIDS (London, England)2018

Increasing prevalence of self-reported HIV preexposure prophylaxis use in published surveys: a systematic review and meta-analysis.

Emiko Kamitani, Megan E Wichser, Adebukola H Adegbite, Mary M Mullins, Wayne D Johnson, Pierre-Cedric Crouch, Theresa Ann Sipe

Open access · greenAbstract readLetterMeta-AnalysisSystematic Review
In one paragraph

Synthesis in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Awareness, Willingness, and Perceived Efficacy of Pre-exposure Prophylaxis among Adolescent Sexual Minority Males.Journal of urban health : bulletin of the New York Academy of Medicine · 2020
    Article
  15. Article
  16. Article
  17. Mapping the Study Characteristics and Topics of HIV Pre-Exposure Prophylaxis Research Literature: A Scoping Review.AIDS education and prevention : official publication of the International Society for AIDS Education · 2019
    Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Emiko KamitaniPrevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Megan E WichserICF International Inc, Atlanta, Georgia.
Adebukola H AdegbiteICF International Inc, Atlanta, Georgia.
Mary M MullinsPrevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Wayne D JohnsonPrevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Pierre-Cedric CrouchSan Francisco AIDS Foundation, San Francisco, California, USA.
Theresa Ann SipePrevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia.
Centers for Disease Control and Prevention · USICF International (United States) · USSan Francisco AIDS Foundation · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

: When combining results from all published surveys, about one in nine global study participants (10.7%) reported ever using preexposure prophylaxis (PrEP) by 2017, a significant increase since US FDA approval in 2012 [odds ratio (OR) = 1.6/year, P < 0.00001]. Moreover, nearly one in six US-based study participants (17.3%) and nearly one in four MSM who met the Centers for Disease Control and Prevention's PrEP indications (24.5%) reported ever using PrEP by 2016. The odds of reporting PrEP use are approximately doubling each year (OR = 1.8/year, P < 0.00001; OR = 2.0/year, P < 0.00001).

Indexed as

Drug UtilizationAdultChemopreventionFemaleHIV InfectionsHomosexuality, MaleHumansMalePre-Exposure ProphylaxisSelf ReportUnited StatesYoung Adult

Identifiers

PMID30096073
PMCPMC6704375
OpenAlexW2886184259

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.